NCT07521748尚未招募1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants
Nanjing Reju Therapeutics Co., Ltd0 个研究点目标入组 24 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 主要终点
- Number of patients with abnormal clinically significant results from physical examination
研究概览
简要总结
This is a Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants.RC017 is a small-molecule drug, being developed as a novel therapeutic treatment for patients with Dry Eye Disease (DED) . This study aims to evaluate the safety, tolerability and pharmacokinetics of RC017 after Single and Multiple Doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female trial participants aged 18 to 55 years old (inclusive);
- •Body Mass Index (BMI) ranging from 19.0 to 26.0 kg/m² (inclusive), with body weight ≥ 50 kg for males and ≥ 45 kg for females;
- •At screening, best corrected visual acuity (BCVA) of both eyes should be ≥ 1.0; in addition, ophthalmic examinations (including assessment of ocular symptoms, slit-lamp microscopy/external eye examination, corneal fluorescein staining, funduscopy, and intraocular pressure measurement) should show no abnormalities in both eyes, or any abnormalities detected should be judged as clinically insignificant by the investigator;
- •Have a full understanding of the trial procedures, voluntarily participate in the trial, and sign a written informed consent form (ICF);
- •Female participants with childbearing potential must have a negative result in the serum pregnancy test at screening. Throughout the entire study period and within 3 months after the study conclusion, all female participants, male participants and their sexual partners must agree to adopt effective contraceptive measures (Note: Contraceptive measures include both pharmacological and non-pharmacological methods, see Appendix 4 for details).
排除标准
- •History of ocular diseases deemed by the investigator as unsuitable for enrollment, including but not limited to dry eye, glaucoma, blepharitis, meibomianitis, allergic conjunctivitis, iritis, uveitis, and/or active ocular inflammation or infection.
- •Prior history of ocular surgeries, including laser refractive surgery and intraocular surgery, etc.
- •Participants who wore contact lenses or cosmetic colored contact lenses within 2 weeks prior to screening, or those requiring contact lens wear during the trial.
- •Use of any prescription or over-the-counter (OTC) medications (including vitamins, antacids, Chinese herbal medicines, dietary supplements, and topical ophthalmic drugs) within 2 weeks prior to screening.
- •Clinically significant abnormalities in vital signs, physical examination findings, laboratory test results (complete blood count [CBC], urine routine, blood biochemistry, coagulation function, infectious disease screening, serum pregnancy test [females only]) or 12-lead electrocardiogram (ECG), as judged by the investigator.
- •History of diseases involving the central nervous, mental, cardiovascular, renal, hepatic, respiratory, metabolic, or musculoskeletal systems, which in the investigator's judgment may compromise participant safety or interfere with study results.
- •Clinically significant history of allergies, especially drug allergies, or known hypersensitivity to any component of the study drug.
- •Daily cigarette smoking > 5 sticks within 3 months prior to the trial.
- •Suspected or confirmed alcohol dependence; average daily alcohol intake > 2 units within 3 months (1 unit = 10 mL pure ethanol, equivalent to 200 mL beer [5% alcohol], 25 mL spirits [40% alcohol], or 83 mL wine [12% alcohol]); or positive alcohol test result.
- •History of drug abuse; or positive urine test for ketamine, morphine, methamphetamine, MDMA, or tetrahydrocannabinol carboxylic acid (THC-COOH).
- •Participation in another clinical trial within 3 months prior to screening.
- •Blood donation or blood loss ≥ 400 mL within 3 months prior to screening.
- •Pregnant or lactating females.
- •Unsuitability for venous blood collection.
- •Vaccination within 30 days prior to screening, or planned vaccination during the study period.
- •Any other conditions deemed by the investigator as unsuitable for enrollment.
研究组 & 干预措施
RC017 Ophthalmic Ointment
Experimental
干预措施: RC017 Ophthalmic Ointment (Drug)
RC017 Ophthalmic Ointment placebo
Placebo Comparator
干预措施: RC017 Ophthalmic Ointment placebo (Drug)
结局指标
主要结局
Number of patients with abnormal clinically significant results from physical examination
时间窗: Day 1-Day 21
The incidence of Treatment-emergent adverse events (TEAEs)
时间窗: Day1 to Day 21
The severity of Treatment-emergent adverse events (TEAEs)
时间窗: Day 1-Day 21
The incidence of Serious adverse events (SAEs)
时间窗: Day 1-Day 21
The severity of Serious adverse events (SAEs)
时间窗: Day 1-Day 21
Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters
时间窗: Day 1-Day 21
Number of participants with abnormal clinically significant clinical laboratory results
时间窗: Day 1- Day 21
次要结局
- Time of maximum observed concentration (Tmax)(Day 1 - Day 14)
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))(Day 1-Day 14)
- AUC from time zero to infinity (AUC0-∞)(Day 1-Day 14)
- Maximum observed concentration (Cmax)(Day 1-Day 14)
- Terminal elimination half life(t1/2)(Day 1-Day 14)
研究者
相似试验
招募中
2 期
A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency SyndromeNCT07432490Oregon Health and Science University16
尚未招募
1 期
A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese WomenBacterial VaginosisNCT07302035Changchun GeneScience Pharmaceutical Co., Ltd.30
已完成
不适用
A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229NCT07285603Matisse Pharmaceuticals15
招募中
1 期
A Clinical Trial Evaluating the Monkeypox Recombinant Protein VaccineHealth VolunteerNCT07495202Shanghai JunTop Biosciences Co., LTD180
招募中
2 期
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisNCT07268638Akebia Therapeutics60